IMUNON to Host R&D Day on September 18th
IMUNON (NASDAQ: IMNN) is hosting an R&D Day on September 18th at the Harvard Club in New York City from 10:00 a.m. to 1:00 p.m. Eastern time. The event follows the announcement of top-line data from their randomized Phase II Ovation 2 Study, which showed an 11.1-month increase in median overall survival for advanced ovarian cancer patients, representing a 35% improvement in survival.
The program will feature ovarian cancer experts, principal investigators from the OVATION 2 Study, and discussions on IMNN-001's potential role in treating advanced ovarian cancer. Management will also discuss next steps for their immunotherapy and prospects for extending patient survival. While in-person attendance is encouraged, a virtual option will be available. Program details and RSVP information will be provided soon.
IMUNON (NASDAQ: IMNN) sta organizzando un R&D Day il 18 settembre presso il Harvard Club di New York City dalle 10:00 alle 13:00 ora Eastern. L'evento segue l'annuncio dei dati preliminari dello studio randomizzato Phase II Ovation 2, che ha mostrato un aumento di 11,1 mesi nella sopravvivenza globale mediana per i pazienti con carcinoma ovarico avanzato, corrispondente a un miglioramento del 35% nella sopravvivenza.
Il programma prevede la partecipazione di esperti di carcinoma ovarico, i principali ricercatori dello studio OVATION 2, e discussioni sul potenziale ruolo di IMNN-001 nel trattamento del carcinoma ovarico avanzato. La direzione discuterà anche i prossimi passi per la loro immunoterapia e le prospettive per estendere la sopravvivenza dei pazienti. Sebbene si incoraggi la partecipazione in persona, sarà disponibile un'opzione virtuale. I dettagli del programma e le informazioni per la registrazione saranno forniti a breve.
IMUNON (NASDAQ: IMNN) está organizando un Día de I+D el 18 de septiembre en el Harvard Club de la ciudad de Nueva York desde las 10:00 a.m. hasta la 1:00 p.m. hora del Este. El evento sigue al anuncio de datos preliminares del estudio aleatorio Phase II Ovation 2, que mostró un incremento de 11.1 meses en la supervivencia global media para pacientes con cáncer de ovario avanzado, representando una mejora del 35% en la supervivencia.
El programa contará con expertos en cáncer de ovario, investigadores principales del estudio OVATION 2 y discusiones sobre el potencial papel de IMNN-001 en el tratamiento del cáncer de ovario avanzado. La dirección también discutirá los próximos pasos para su inmunoterapia y las perspectivas de extender la supervivencia de los pacientes. Si bien se alienta la asistencia en persona, habrá una opción virtual disponible. Los detalles del programa y la información para confirmar asistencia se proporcionarán pronto.
IMUNON (NASDAQ: IMNN)은 연구개발의 날을 9월 18일 뉴욕시 하버드 클럽에서 오전 10시부터 오후 1시(동부 표준시)까지 개최합니다. 이번 행사는 무작위 Phase II Ovation 2 연구의 최종 데이터 발표 후 진행되며, 이 연구는 진행성 난소암 환자에 대해 중위 생존 기간이 11.1개월 증가한 결과를 보여주었으며, 생존률이 35% 개선되었음을 의미합니다.
프로그램에는 난소암 전문가와 OVATION 2 연구의 주요 연구자들이 참여하고, IMNN-001의 향후 진행 가능성에 대한 논의가 이어질 것입니다. 경영진은 또한 이들의 면역요법 다음 단계와 환자 생존 연장 가능성에 대해서도 설명할 것입니다. 대면 참석이 권장되지만 가상 참석 옵션도 제공될 예정입니다. 프로그램 세부 사항과 RSVP 정보는 곧 제공될 것입니다.
IMUNON (NASDAQ: IMNN) organise une Journée de R&D le 18 septembre au Harvard Club de New York de 10h00 à 13h00, heure de l'Est. Cet événement fait suite à l'annonce des données préliminaires de leur étude randomisée Phase II Ovation 2, qui a montré une augmentation de 11,1 mois de la survie globale médiane pour les patients atteints d'un cancer de l'ovaire avancé, représentant une amélioration de 35% de la survie.
Le programme présentera des experts en cancer de l'ovaire, des chercheurs principaux de l'étude OVATION 2, et des discussions sur le rôle potentiel d'IMNN-001 dans le traitement du cancer de l'ovaire avancé. La direction discutera également des prochaines étapes de leur immunothérapie et des perspectives d'extension de la survie des patients. Bien que la participation sur place soit encouragée, une option virtuelle sera également disponible. Les détails du programme et les informations pour s'inscrire seront fournis prochainement.
IMUNON (NASDAQ: IMNN) veranstaltet einen Forschung und Entwicklungstag am 18. September im Harvard Club in New York City von 10:00 bis 13:00 Uhr Eastern Zeit. Die Veranstaltung folgt der Ankündigung von Stammdaten aus ihrer randomisierten Phase II Ovation 2 Studie, die ein 11,1-monatiges Plus in der medianen Gesamtüberlebenszeit für Patienten mit fortgeschrittenem Eierstockkrebs zeigt und eine 35%ige Verbesserung der Überlebensraten darstellt.
Das Programm wird Eierstockkrebs-Experten, Hauptforscher der OVATION 2 Studie und Diskussionen über IMNN-001s potenzielle Rolle bei der Behandlung von fortgeschrittenem Eierstockkrebs umfassen. Das Management wird auch über die nächsten Schritte ihrer Immuntherapie und die Perspektiven zur Verlängerung der Patientensurvival sprechen. Während die persönliche Teilnahme empfohlen wird, wird auch eine virtuelle Option verfügbar sein. Programmdetails und weitere Informationen zur Anmeldung werden bald bereitgestellt.
- None.
- None.
R&D Discussion in New York City to Review IL-12’s Potential to Treat Ovarian Cancer
Program Features Ovarian Cancer Thought Leaders, OVATION 2 Study Investigators, and Oncology Experts
LAWRENCEVILLE, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, invites investors to mark their calendars for its R&D Day event to be held at the Harvard Club in New York City on September 18th from 10:00 a.m. to 1:00 p.m. Eastern time.
The R&D Day event follows Imunon’s announcement of top-line data from its randomized Phase II Ovation 2 Study. These data suggest an 11.1 month increase in median OS in the intent-to-treat population, indicating a remarkable
The program will feature ovarian cancer thought leaders, principal investigators from the Company’s Phase 2 OVATION 2 Study of IMNN-001, a review of the study’s topline results and how the data will inform the Phase 3 registration study, and a discussion about the potential role of IMNN-001 in the treatment of advanced ovarian cancer. In addition, management will discuss next steps with its powerful immunotherapy and the prospects for extending patient survival.
We strongly encourage in-person attendance to facilitate networking and direct engagement with our speakers and management team. However, for those unable to attend in person, a virtual participation option will also be available.
Program details including speakers will be upcoming, along with an opportunity to RSVP for participation.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the delivery of DNA-coded viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 clinical studies. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101). IMUNON will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Contacts:
| IMUNON | LHA Investor Relations |
| David Gaiero | Kim Sutton Golodetz |
| 978-376-6352 | 212-838-3777 |
| dgaiero@imunon.com | kgolodetz@lhai.com |
# # #
FAQ
When and where is IMUNON's R&D Day event taking place?
What were the key findings from IMUNON's Phase II Ovation 2 Study?
What will be discussed during IMUNON's R&D Day event?
Can investors participate in IMUNON's R&D Day virtually?
What is IMNN-001 and what is its potential application?
